THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT
|
|
|
- ひとお なつ
- 5 years ago
- Views:
Transcription
1 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS ,866 JA
2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT
3 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
4 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June ,866 FQs 30 Streptococcus pyogenes Streptococcus pneumoniae Moraxella catarrhalis Haemophilus in uenzae FQs S. pneumoniae S. pyogenes H. in uenzae - H. in uenzae % % % %FQs Escherichia coli levo oxacin LVFX 29.3% LVFX % % % % % 2009 LVFX 500 mg 1 1 Klebsiella pneumoniae FQs E. coli Staphylococcus aureus MRSA FQs sita oxacin 51.6% FQs 10% S. aureus % staphylococcifqs staphylococci MRSA Pseudomonas aeruginosa FQs % % P. aeruginosa 2.3% 0.3% 2007 Acinetobacter spp. FQs Acinetobacter baumannii imipenem 2.4% 13 Neisseria gonorrhoeae FQs % Ceftriaxone CTRX % CTRX 17 FQs staphylococci Enterococcus faeciump. aeruginosa N. gonorrhoeae E. coli 20% % E. coli 70% 80% Staphylococcus aureus MRSA 1 - Extended-spectrum
5 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS lactamase: ESBL Escherichia coli Klebsiella pneumoniae 2 - MBL 3 DNA 4 Pharmacokinetics/ Pharmacodynamics PK-PD PK-PD FQs FQs FQs 1992 FQs FQs 5 7 FQs E. coli 2000 FQs FQs ESBL Table 1. The number of isolates.
6 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June , ,866 Table 1 Table BML 80 C Table 2. List of the levo oxacin surveillance group.
7 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS Levo oxacin LVFX cipro oxacin CPFX tosufloxacin TFLX sitafloxacin STFX benzylpenicillin PCG ampicillin ABPC clavulanic acid amoxicillin CVA/AMPC piperacillin PIPC oxacillin MPIPC cefaclor CCL cefotiam CTM cefdinir CFDN cefpodoxime CPDX ceftazidime CAZ cefotaxime CTX ceftriaxone CTRX cefpirome CPR meropenem MEPM panipenem PAPM imipenem IPM aztreonam AZT minocycline MINO clarithromycin CAM azithromycin AZM vancomycin VCM sulfamethoxazole trimethoprim ST gentamicin GM amikacin AMK linezolid LZD chloramphenicol CP 3. MIC Neisseria gonorrhoeae MIC Table 3 Clinical and Laboratory Standards Institute CLSI 8 MIC Streptococcus pneumoniae S. pneumoniae PSSP PCG MIC 0.06 g/ml S. pneumoniae PRSP PCG MIC 2.0 g/ ml CLSI 4. Haemophilus in uenzae - Haemophilus in uenzae - 5. QRDR Table 4 QRDR 9 LVFX MIC 20% 20 MIC 20 LVFX MIC 10 MIC Extendedspectrum -lactamase: ESBL E. coli K. pneumoniae Proteus mirabilis CTX CVA CAZ CVA MIC CTX CAZ MIC 3 ESBL PCR ESBL 7. Pseudomonas aeruginosa MDRP P. aeruginosa MIC CPFX 4.0 g/ml IPM 16 g/ml AMK 32 g/ml MDRP 8. Acinetobacter baumannii A. baumannii VITEK2 Sysmex
8 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 Table 3. Test drugs and the range of their concentrations for determination of MIC.
9 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS Table 4. Target species and genes of QRDR measurement. Table 5. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI Table 5 Table 8 Streptococcus pyogenes CPFX 81.6% MINO 84.8% CAM 56.0% AZM 55.1% 98% Table 5 STFX FQs 5 15 QRDR %QRDR parc LVFX MIC g/ml
10 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 Table 6. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI parc 2 gyra parc MIC 0.5 g/ml 42 1 parc MIC 0.25 g/ml 20 1 MIC g/ml 8 2 parc LVFX 2 S. pneumoniae FQs CPFX 80.2% 98% MIC g/ml STFX MIC g/ml Table 5 QRDR LVFX 10 QRDR gyra parcgyra pare 5 LVFX 145 MIC 2.0 g/ml 12 gyra parc pare 4 MIC 1.0 g/ml 90 parc 1 MIC 0.5 g/ml QRDR FQs VCM CVA/AMPC CTRX PAPM 100% 99.5% 97.4% 98.2% IPM 79.0% % 80%
11 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS Table 7. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI. Table 5 PSSP PISP PRSP 48.0% 43.4% 8.6% PRSP CTRX 1.8% CCL 100% CTM 98.2% CFDN 98.2% CPDX 91.2% S. aureus MSSA FQs MIC g/ml % STFX FQs 90%ABPC 43.2% CAM 75.3% AZM 74.8% 80% Table 6 FQs MRSA MIC 90 STFX 8.0 g/ml 16 g/ml 64 g/ml FQs STFX 51.6% 10% % FQs VCM LZD % VCM LZD Table 6 VCM MRSA MIC 2.0 g/ ml MRSA CA-MRSA - LVFX CAM MINO % staphylococci
12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 Table 8. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI. FQs MIC g/ml FQs CAM 76.7% AZM 75.9% % FQs MSSA STFX % Table 7 staphylococci MIC 90 MRSA STFX MIC g/ml MINO 96.7% FQs MIC g/ml % VCM LZD Table 7 Enterococcus faecalis FQs % 100% ABPC VCM Table 8 Enterococcus faecium VCM 99.8% LZD 98.0% MINO 50.8% STFX 30.5% 15% Table 8 2 Table 9 Moraxella catarrhalis FQs MIC g/ml LVFX, CPFX, STFX
13 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS Table 9. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI. ABPC 15.5% CVA/AMPC - CTM 88.7% 95% N. gonorrhoeaefqs MIC 90 LVFX, CPFX, TFLX g/ml STFX 0.5 g/ml FQs MIC 90 CTRX 0.25 g/ml AZM 2.0 g/ml CFDN 1.0 g/ml MINO 1.0 g/ml CAM 4.0 g/ ml ABPC 4.0 g/ml CVA/AMPC 4.0 g/ ml ABPC CVA/AMPC CTRX4 5.0% 4 3 Table 10 Table 15 E. coli FQs MIC 90 STFX 1.0 g/ml g/ml STFX 91.9% % 30% % Table 10 LVFX gyra parc LVFX QRDR MIC g/ml % gyra gyra 0.5 g/ml g/ml 3 parc
14 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 Table 10. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI g/ml QRDR ESBL % K. pneumoniae FQs MIC g/ml FQs % E. coli Table 10 E. coli LVFX QRDR MIC g/ml % gyra % QRDR gyra parc MIC 16 g/ml ESBL29 4.3% Citrobacter spp. Enterobacter spp. FQs MIC g/ml g/ mlfqscitrobacter spp % Enterobacter spp % Citrobacter spp. PAPM 99.8% IPM 96.5% Enterobacter spp. PAPM 93.6% IPM 86.8% Table 11 P. mirabilis FQs MIC 90 STFX 1.0 g/ml FQs g/ml % MINO 2.0% ST CP 60.7% 67.1% FQs Table 12 ESBL % Proteus FQs MIC g/ml %
15 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS Table 11. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI. FQs CAZ, CTX, CPDX 80% Table 12 Serratia marcescens FQs MIC g/ml % CAZ PAPM 98.3% 97.8% Table 13 Salmonella spp. FQs MIC g/ml 100% FQs ST 90% Table 13 H. in uenzae FQs MIC g/ml Table 14 STFX FQs LVFX gyra MIC g/ml; 9.2% 0.03 g/ml; 17.4% 0.06 g/ml; 60.0% g/ ml; 69.2% - BLNAR H. in uenzae % %CFDN - BLPAR % CVA/AMPC CVA/ AMPC MIC 8.0 g/ml 23 Acinetobacter spp. FQs MIC g/ml % IPM, MINO, PAPM, CAZ 96.9%, 96.5%, 95.0%, 89.8%
16 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 Table 12. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI. 50% Table 14 IPM % PAPM % IPM A. baumannii P. aeruginosa FQs MIC g/ml % FQs STFX 80.0% 80% AMK 96.4% PIPC 93.3% GM 89.7% CAZ 86.0% MEPM 85.9% P. aeruginosa FQs MIC g/ ml % FQs AMK 98.3% GM 94.4% PIPC 92.7% Table 15 CPFX IPM AMK MDRP 2.3% 140.3% 2 MDRP % 10 50% 1 S. pyogenes FQs CPFX 81.6% 98% M N DNA
17 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS Table 13. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI. emm 10 prtf1-11 S. pyogenes LVFX 6 2 FQs S. pneumoniae 52.0% 2007 CAM, AZM 85% 12,13 ermb 23S RNA mefa ermb MIC ermb mefa
18 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 Table 14. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI. 14 S. pneumoniae 15 S. pneumoniae FQs CPFX 19.8%1.5% FQs DNA IV QRDR LVFX QRDR MIC 2.0 g/ml 12 gyra parc pare 4 MIC 1.0 g/ml 90 parc 1 CLSI LVFX MIC 2.0 g/ml parc 17 QRDR FQs CPFX MIC LVFX FQs 18 FQs 19 FQs MSSA FQs 88% MRSA FQs
19 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS Table 15. In vitro activities of drugs against clinical isolates and percentages of isolates susceptible to test drugs on the basis of CLSI VCM VCM MRSA MIC 2.0 g/ml % % % VCM MIC 2.0 g/ml VCM VanA MRSA FQs E. coli FQs E. coli FQs % LVFX % % % % % % % % LVFX 500 mg 1 1 C max 1C max LVFX 61.6% 76.3%66.0%77.2% % 18% 21 MIC parc FQs E. coli
20 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 FQs K. pneumoniae FQs E. coli K. pneumoniae FQs 22 E. coli LVFX QRDR E. coli, K. pneumoniae, P. mirabilis CFDN % CFDN ESBL PCR E. coli % K. pneumoniae % P. mirabilis % ESBL 2007 E. coli % K. pneumoniae % P. mirabilis % ESBL 23 E. coli P. mirabilis E. coli ESBL 2007 FQs ESBL E. coli % K. pneumoniae % P. mirabilis % LVFX ESBL LVFX 2007 ESBL E. coli ST131 FQs H. in uenzae BLPAR BLNAR BLPAR BLNAR 24 BLNAR BLPAR 6 H. in uenzae BLNAR CFDN H. in uenzae - PBPs BLNAR FQs 98% QRDR FQs 25 LVFX MIC g/ml gyra g/ml; 9.2%, 0.03 g/ml; 13.0%, 0.06 g/ml; 60.0%, g/ ml; 61.5% FQs P. aeruginosa FQs 8 FQs P. aeruginosa FQs MDRP 26 MDRP 2.3% 140.3% 2
21 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS MDRP MDRP % % 1 Acinetobacter spp. 95% 15 Acinetobacter spp. 13 A. baumannii IPM N. gonorrhoeae CTRX 2007 CTRX4 5.0% 4 CTRX 17 FQs staphylococci E. faeciump. aeruginosa, N. gonorrhoeae, E. coli 20% % E. coli 70% 80% 1 MINE, Y.; W. HIGUCHI, K. TAIRA, et al.: Nosocomial outbreak of multidrug-resistant USA300 methicillin-resistant Staphylococcus aureus causing severe furuncles and carbuncles in Japan. J. Dermatol. 38: , FOUQUET, M.; V. MORANGE & F. BRUYÈRE: Five years following of infections with extendedspectrum beta-lactamase producing enterobacteriaceae. Prog. Urol. 22: 17 21, HIRAKATA, Y.; K. IZUMIKAWA, T. YAMAGUCHI, et al.: Rapid detection and evaluation of clinical characteristics of emerging multiple-drugresistant Gram-negative rods carrying the metallo- -lactamase gene bla IMP. Antimicrob. Agents Chemother. 42: , I 92: , YAMAGUCHI, K.; A. OHNO & Levo oxacin Surveillance Group: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to Diagn. Microbiol. Infect. Dis. 52: , ,639 Jpn. J. Antibiotics 59: , ,919 Jpn. J. Antibiotics 62: , Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; Twenty-First informational Supplement M100-S21. Wayne, PA, GERISCHER, U.: Direct sequencing of DNA produced in a polymerase chain reaction. Meth. Mol. Biol. 167: 53 61, PIRES, P.; D. ROLO, A. MORAIS, et al.: Description of macrolide-resistant and potential virulent clones of Streptococcus pyogenes causing asymptomatic colonization during in the Lisbon area. Eur. J. Clin. Microbiol. Infect.
22 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 Dis.: published online, SELA, S. & A. BARZILAI: Why do we fail with penicillin in the treatment of group A Streptococcus infections? Ann. Med. 31: , FELMINGHAM, D.; R. R. REINERT, Y. HIRAKATA, et al.: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 50: 25 37, SONG, J. H.; S. I. JUNG, K. S. KO, et al.: High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia an ANSORP study. Antimicrob. Agents Chemother. 48: , FARRELL, D. J.; S. G. JENKINS, S. D. BROWN, et al.: Emergence and spread of Streptococcus pneumoniae with erm B and mef A resistance. Emerg. Infect. Dis. 11: , NIEDERMAN, M. S.; J. B. JR. BASS, G. D. CAMPBELL, et al.: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am. Rev. Respir. Dis. 148: , WEIGEL, L. M.; G. J. ANDERSON, R. R. FACKLAM, et al.: Genetic analyses of mutations contributing to uoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: , SUE, L.; B. DARRIN, M. ALLISON, et al.: Antimicrobial susceptibility breakpoints and rst-step parc mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. 9: , PIDDOCK, L. J.; M. JOHNSON, V. RICCI, et al.: Activities of new uoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob. Agents Chemother. 42: , ICIAR, R. A.; R. BELÉN, R. ESTHER, et al.: Clonal spread of levo oxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to Antimicrob. Agents Chemother. 55: , REINERT, R. R.; D. E. LOW, F. ROSSI, et al.: Antimicrobial susceptibility among organisms from the Asia/Paci c Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J. Antimicrob. Chemother. 60: , HSUEH, P. R.; D. J. HOBAN, Y. CARMELI, et al.: Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia- Paci c region. J. Infect. 63: , LEE, K.; M. A. LEE, C. H. LEE, et al.: Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and Yonsei Med. J. 51: , KOMATSU, M.; M. AIHARA, K. SHIMAKAWA, et al.: Evaluation of MicroScan ESBL con rmation panel for Enterobacteriaceae-producing, extended-spectrum beta-lactamases isolated in Japan. Diagn. Microbiol. Infect. Dis. 46: , TRISTRAM, S.; M. R. JACOBS & P. C. APPELBAUM: Antimicrobial resistance in Haemophilus in uenzae. Clin. Microbial. Rev. 20: , KIM, I. S.; N. Y. LEE, S. KIM, et al.: Reduced levo oxacin susceptibility in clinical respiratory isolates of Haemophilus in uenzae is not yet associated with mutations in the DNA gyrase and topoisomerase II genes in Korea. Yonsei Med. J. 52: , TAKEYAMA, K.; Y. KUNISHIMA, M. MATSUKAWA, et al.: Multidrug-resistant Pseudomonas aeruginosa isolated from the urine of patients with urinary tract infection. J. Infect. Chemother. 8: 59 63, 2002
23 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS In vitro susceptibilities to levo oxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010 KEIZO YAMAGUCHI Department of Advanced and Integrated Analysis of Infectious Diseases, Toho University School of Medicine AKIRA OHNO, YOSHIKAZU ISHII and KAZUHIRO TATEDA Department of Microbiology and Infectious Diseases, Toho University School of Medicine MORIHIRO IWATA Department of Clinical Laboratory, Toho University Omori Medical Center and Levo oxacin Surveillance Group KOUJI AKIZAWA and CHIKARA SHIMIZU Hokkaido University Hospital TASUKU HAYASHI Muroran City General Hospital Asahikawa City Hospital MITSUO KAKU, HIROYUKI KUNISHIMA and MIHO KITAGAWA Tohoku University Graduate School of Medicine MAKOTO MIKI Japanese Red Cross Sendai Hospital CHIZUKO KAWAMURA Aomori Prefectural Central Hospital MINORU YASUJIMA Hirosaki University School of Medicine & Hospital HIROMI TASHIRO, HIROKO HORIUCHI and YOSEI KATAYAMA Hachinohe City Hospital AKIRA SUWABE and MAKIKO KUROTA Iwate Medical University Hospital KENJI KIKUCHI and SATORU KUROKI Yuri-Kumiai General Hospital KATSU HIRAYAMA, TOSHIAKI TAKAHASHI and TAKANORI GOTOU JA Akita Kouseiren Hiraka General Hospital KEITA MORIKANE and REIKO OTA Yamagata University Hospital TAKUO NAKAGAWA Kozirakawa Shiseidou Hospital KYOJI MORIYA The University of Tokyo MITSURU MURATA Keio University School of Medicine AKIKO YONEYAMA Toranomon Hospital SHIGEMI KONDOU and SHIGEKI MISAWA Juntendo University School of Medicine IMAO SEKINE and JOJI SHIOTANI The Cancer Institute Hospital of JFCR TOMOHIRO NAKAYAMA and MICHIKO YAGOSHI Nihon University Itabashi Hospital HAJIME HORIUCHI and YOKO TAZAWA NTT Medical Center Tokyo
24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 HARUSHIGE KANNO and MASANORI AIHARA Takane Hospital KENICHIRO YAMAZAKI Saitama Red Cross Hospital HIDEYUKI OKAMOTO Kawaguchi Municipal Medical Center KOSUKE HARUKI, JUNKO YAZAWA and EIKO NAGANO Dokkyo Medical University, Koshigaya Hospital MOTOI OKADA, YASUKO FUKUDA and HIROMI IKARI Koshigaya Municipal Hospital SHIGEFUMI MAESAKI and GIICHI HASHIKITA Saitama Medical University Hospital MIDORI SUMITOMO Yokohama City University Hospital EIJI MIYAJIMA Yokohama City University Medical Center TAKEFUMI SAITO Ibarakihigashi National Hospital NOBUYUKI TANIGUCHI Jichi Medical School AKIRA HISHINUMA, YOSHITAKA YAMAMOTO and YUKI OKAMOTO Dokkyo Medical University Hospital NOBUO YAMANE, RYOU MARUYAMA and CHIEKO KAWASHIMA Ashikaga Red Cross Hospital MASAMI MURAKAMI, SACHIE YOMODA and TETSUO MACHIDA Gunma University Hospital YUKIO OZAKI and TAKASHI UCHIDA University of Yamanashi Hospital HISASHI BABA Nagoya University Hospital YASUYUKI SUGIURA, KONOMI KONDO and TAKAKO YAMADA Aichi Prefectural Welfare Federation of Agricultural Co-operative Associations Anjo-kosei Hospital HIDEO GONDA and IKUO YAMAGUCHI Toyohashi Municipal Hospital TOSHIYUKI AKAHORI and KEIICHI UEMURA Fukuroi Municipal Hospital MASATO MAEKAWA Hamamatsu University School of Medicine HITOSHI YOSHIMURA Mie Prefectural Shima Hospital KANAME NAKATANI, YOSHIKO MATSUSHIMA and TSUTOMU NOBORI Mie University Hospital YOSHINORI FUJIMOTO, YUKO ASANO and ASAMI MORINAGA Ogaki Municipal Hospital SHINICHI FUJITA and YASUKO SENDA Kanazawa University Hospital YUKIO HIDA, MASANORI YAMASHITA and HARUYOSHI YOSHIDA University of Fukui Hospital SATOSHI ICHIYAMA Kyoto University Hospital HIDETOSHI OKABE, MASAYO SHIGETA and KAORU SHIMIZU Shiga University of Medical Science HIROYA MASAKI, HITOSHI HEIJYOU and HIDEO NAKAYA Kansai Medical University Takii Hospital TAKAYUKI TAKUBO, TADASHI KUSAKABE and TOMONORI HIGASHIYAMA Osaka Medical College Hospital HIROKO YOSHIDA and HIROSHI MORISHITA Osaka Prefectural Medical Center for Respiratory and Allergic Diseases
25 June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS SHUJI MATSUO, HISASHI KONO and SAORI FUKUDA Tenri Hospital REIKO SANO Nara Medical University Hospital YOSUKE YUZUKI, NORIO IKEDA and MASAYA IDOMUKI Japanese Red Cross Society Wakayama Medical Center GO YAMAMOTO Nishi-kobe Medical Center SYOHIRO KINOSHITA and SEIJI KAWANO Kobe University Hospital MASAO DOI, YAEKO WATANABE and SATOMI SHIMIZU Hirosima Prefectural Hospital MIKIO OKA and YOSHIHIRO KOBASHI Kawasaki Medical School NOBUCHIKA KUSANO Okayama University Hospital HIROMITSU FUJIWARA, HIROMI MUROTA and SHOTA MORISHITA Tottori University Hospital ATSUSHI NAGAI, HIDEHIKO MORIYAMA and YUKI TANIGUCHI Shimane University Hospital KIYOSHI NEGAYAMA and KOJI MURAO Kagawa University Hospital HITOSHI MIYAMOTO Ehime University Hospital TETSURO SUGIURA and TAMAE MORITA Kochi Medical School Hospital HIROMI TOU and AKIRA MATSUNAGA Fukuoka University Hospital DONGCHON KANG and MAKIKO KIYOSUKE Kyushu University Graduate School of Medical Sciences KOICHI MASHIBA Kitakyushu Municipal Medical Center KATSUNORI YANAGIHARA, JUNICHI MATSUDA and SHIGERU KOHNO Nagasaki University Hospital YOSUKE AOKI, ZENZO NAGASAWA and KOJI KUSABA Saga Medical School Hospital KAZUFUMI HIRAMATSU and TETSUNORI SAIKAWA Oita University Hospital HIROAKI MIYANOHARA Kagoshima University Hospital YUJI SAEKI, ICHIRO TAKAJO and AKIHIKO OKAYAMA University of Miyazaki Hospital NOBUHISA YAMANE and ISAMU NAKASONE Clinical Laboratories, University Hospital of the Ryukyus Postmarketing surveillance of levo oxacin LVFX has been conducted continuously since The present survey was performed to investigate in vitro susceptibility of recent clinical isolates in Japan to 30 selected antibacterial agents, focusing on uoroquinolones FQs. The common respiratory pathogens Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae continue to show a high susceptibility to FQs. In contrast, widely-prevailing resistance to macrolides was markedly noted among S. pneumoniae and S. pyogenes. Regarding H. in uenzae, the prevalence of -lactamase-negative ampicillinresistant isolates has been increasing year by year 25.8% in 2002, 40.0% in 2004, 50.1% in 2007, and 57.9% in Enterobacteriaceae showed high susceptibility to FQs, however,
26 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 prevalence of LVFX-resistant Escherichia coli, including intermediate resistance, was 29.3%, showing an increase over time. Nevertheless, the increase in the prevalence of LVFX-resistant E. coli isolates has slowed since % in 2000, 11.8% in 2002, 18.8% in 2004, 26.2% in 2007, and 29.3% in 2010, suggesting the in uence of LVFX 500 mg tablets since its approval in Another Enterobacteriaceae member, Klebsiella pneumoniae, showed low resistance to FQs, in contrast with E. coli. In methicillin-resistant Staphylococcus aureus MRSA, the percentage of FQ-susceptible isolates was low, at 51.6% for susceptibility to sita oxacin, and at only around 10% for susceptibility to other FQs. However, methicillin-susceptible S. aureus MSSA isolates were highly susceptible to FQs, with the percentage ranging from 88.5% to 99.1%. The prevalence of FQs-resistant isolates in methicillin-resistant coagulase-negative staphylococci was higher than that in methicillin-susceptible coagulase-negative staphylococci, although it was lower than the prevalence of FQ-resistance in MRSA. The prevalence of FQsresistant Pseudomonas aeruginosa isolates derived from urinary tract infections UTIs was %, higher than the prevalence of % in P. aeruginosa isolates from respiratory tract infections RTIs. While this trend was consistent with the results of previous surveillance, gradual decreases were noted in the prevalence of FQ-resistant P. aeruginosa isolates derived from UTIs. The prevalence of multidrug-resistant P. aeruginosa was 2.3% among isolates derived from UTIs and 0.3% among isolates from RTIs, a decrease from the results of Acinetobacter spp. showed high susceptibility to FQs. Imipenem-resistant Acinetobacter baumannii, which is currently an emerging issue, was detected at a prevalence of 2.4% 13 isolates. Neisseria gonorrhoeae showed a high resistance of %, to FQs. Ceftriaxone CTRX continued to show 100% susceptibility until 2007, but the present survey revealed the advent of resistance to CTRX in some clinical isolates. The result of the present survey indicated that although methicillin-resistant staphylococci, Enterococcus faecium, P. aeruginosa from UTIs, N. gonorrhoeae, and E. coli showed resistance of about 20% or more % against the FQs which have been used clinically for over 17 years, the trends observed were similar to the results of previous surveillance. While FQ resistance has been prevailing in E. coli, E. coli still shows more than 70% susceptibility to FQs. The other bacterial species maintained high susceptibility rates of greater than 80%, against FQs.
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79)
346 ( 78) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 2007 72 12,919 NTT THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 347 ( 79) 348 ( 80) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 THE JAPANESE JOURNAL OF
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
R06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb. 2012 CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon
Feb. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 1 1 2008 2009 2011 10 25 2008 6 2009 4 Streptococcus pneumoniae 377 penicillin-binding protein: PBP 2004 S. pneumoniae 160 2 2 THE JAPANESE JOURNAL OF
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%
207 ( 1 ) Cefditoren pivoxil G 2010 2 2 2006 3 Cefditoren pivoxil CDTR-PI MS 10% CDTR-PI 305 2,144 2,006 1,958 1.79% 36 2,006 26 (1.30%) CDTR-PI CDTR-PI (9 mg/kg/day) 1.5 2 (2.70%) 2 (1.92%) 93.5% 1,831
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS ,4 2,4 2,4 2,3,4 2,3,4 2,3, ,3, Garenoxacin GRNX Levofloxacin LV
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 27 27 1,4 2,4 2,4 2,3,4 2,3,4 2,3,4 2 1 2,3,4 1 2 3 4 2015 10 21 9 Garenoxacin GRNX Levofloxacin LVFX Sitafloxacin STFX Moxifloxacin MFLX Pharmacokinetics-Pharmacodynamics
VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
日本化学療法学会雑誌第50巻第6号
13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S.
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
R01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc
J Infect Chemother (2012) 18:609 620 DOI 10.1007/s10156-012-0434-3 SURVEILLANCE Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab
June 2011 THE JAPANESE JOURNAL OF ANTIBIOTICS 64 23 179 ( 63 ) A b cefditoren pivoxil 5 amoxicillin 10 1,2) 1,3) 1) 1) 1) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 2011 4 8 2007 5 2009 4 A b GAS cefditoren pivoxil
The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
CHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
ｽﾗｲﾄﾞ ﾀｲﾄﾙなし
第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE
Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Ci
Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Citation 泌尿器科紀要 (1992), 38(11): 1215-1223 Issue Date
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali
CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical
CHEMOTHERAPY
VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter
Supplementary data
Supplementary data Supplement to: Onozuka D, Gasparrini A, Sera F, Hashizume M, Honda Y. Future projections of temperature-related excess out-of-hospital cardiac arrest under climate change scenarios in
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1
Dec. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 46 431 ( 45 ) 2006 1) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10)
日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004